| Price | 203.25p on 04-03-2026 at 06:00:04 |
|---|---|
| Change | 0.00p 0% |
| Buy | 0.00p |
| Sell | 0.00p |
| Last Trade: | Sell 2.00 at 198.98p |
| Day's Volume: | 0 |
| Last Close: | 203.25p |
| Open: | 0.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.75b |
| VWAP: | 0.00p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 2 | 198.98p | Ordinary |
16:03:44 - 03-Mar-26 |
| Sell* | 1 | 198.98p | Ordinary |
15:55:27 - 03-Mar-26 |
| Sell* | 733 | 198.50p | Automatic Execution |
15:16:49 - 03-Mar-26 |
| Buy* | 6 | 208.265p | Ordinary |
15:15:44 - 03-Mar-26 |
| Buy* | 10 | 204.952p | Suspected BUY Trade |
14:56:38 - 03-Mar-26 |
| Buy* | 3 | 209.00p | SI Trade |
14:56:37 - 03-Mar-26 |
| Unknown* | 0 | 209.00p | SI Trade |
14:56:37 - 03-Mar-26 |
| Buy* | 8 | 209.00p | SI Trade |
14:56:37 - 03-Mar-26 |
| Sell* | 17 | 205.00p | Automatic Execution |
14:56:37 - 03-Mar-26 |
| Sell* | 50 | 205.00p | Automatic Execution |
14:56:37 - 03-Mar-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 6th Feb 2026 8:30 am | RNS | HUTCHMED to Announce 2025 Final Results |
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am | RNS | Blocklisting Six Monthly Return |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |